By Jeff Overley ( February 11, 2013, 4:23 PM EST) -- Overcoming serious safety concerns, Celgene Corp. on Monday announced that its blood cancer drug Revlimid has won approval in China, a development that came just days after the company said U.S. regulators would expedite their review of expanded use of the medicine....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.